FDA Approves Frontline Atezolizumab Plus Chemo for Metastatic Non-Squamous NSCLC

The FDA approved atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer with no  EGFR or ALK genomic tumor aberrations.

Source: CancerNetwork - December 4, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news